<DOC>
	<DOCNO>NCT02817178</DOCNO>
	<brief_summary>The investigator recently identify promiscuous HLA-DR-derived epitope human telomerase reverse transcriptase ( TERT ) call universal cancer peptide ( UCP ) , study tumor-specific CD4+ T cell response . The investigator find high frequency naturally occur UCP-specific TH1 cell long term survival metastatic colorectal cancer ( CRC ) previously treat 5 fluoro-uracil -oxaliplatin ( Folfox ) +/- bevacizumab regiment ( Godet et al . OncoImmunology 2012 unpublished data ) . Epitopes-CRC02 French prospective multicenter study evaluate post chemotherapy post surgery modulation host tumor-specific CD4 TH1 cell response metastatic colorectal cancer patient correlation progression-free survival .</brief_summary>
	<brief_title>Study Validation Immunological Biomarkers Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Performance status ECOGWHO 0 , 1 2 Metastatic colorectal cancer Histologically prove sign write informed consent previous treatment ( chemotherapy , target therapy , surgery ) metastatic disease history autoimmune disease patient immunotherapy systemic treatment immunosuppressive drug stop less 6 month enrollment study . corticoid â‰¥ 1mg/kg acute chronic infectious disease treatment stop less six month malignancy within last 5 year , except adequately treat carcinoma situ cervix squamous carcinoma skin , adequately control limited basal cell skin cancer . pregnancy , breastfeed absence adequate contraception fertile patient patient medical psychiatric condition disease would make patient inappropriate entry study . patient guardianship , curator protection justice .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>